Good MorningEquities retreated on Monday, extending the sell-off that began last week in the wake of the CPI report. The selling is driven in part by fears of rising inflation, in part by fears of FOMC activity after so long without, and in part by geopolitical fear centered on Russia and Ukraine. The threat of war could destabilize the already overstrained global supply chain but it looks like the powers-that-be will continue to talk, for now, while Putin slowly builds his forces along the border.
This week, the PPI data will be in sharp focus as it is expected to accelerate on a month-to-month basis. The consensus is for producer level prices to rise 0.5% on top of the previous month's 0.2% and put YOY increases even closer to double-digits. The risk for the market is that PPI will come in above consensus and increase the expectations for a 50 basis point interest rate hike at the March FOMC meeting. Featured: WARNING: Your download link will expire (BehindtheMarkets) 
|
Politics | | | European benchmarks jumped early Tuesday as the Kremlin and the West held out the possibility of a diplomatic path out of the Ukraine crisis. Asian shares were mostly lower.
France's CAC 40 surged 1.6% in early trading to 26,865.19, while Germany's DAX jumped 1.2% to 15,294.66. Britai... Read the Full Story |
|
|
Politics | | | European benchmarks jumped early Tuesday as the Kremlin and the West held out the possibility of a diplomatic path out of the Ukraine crisis. Asian shares were mostly lower.
France's CAC 40 surged 1.6% in early trading to 26,865.19, while Germany's DAX jumped 1.2% to 15,294.66. Britai... Read the Full Story |
|
Markets | | | In the spirit of the Winter Olympics, Occidental Petroleum, Halliburton, and Schlumberger currently sit in the gold, silver, and bronze positions, respectively. Will they be at the podium during 2022’s closing ceremonies? Read the Full Story |
|
From Our PartnersMost people think inflation is today’s biggest financial risk. But, sadly, that doesn’t even begin to explain what is about to happen.
According to tech expert Jeff Brown, the biggest headlines of 2022 will have nothing to do with inflation… | | | | Click to see now, before it’s front-page news |
|
Markets | | |
U.S. national security advisor Jake Sullivan announced on Sunday that a Russian attack on Ukraine could happen at any time. Unfortunately, it looks like Ukraine's citizens agree due to widespread panic in Ukraine.
In talks with Russian leader Vladimir Putin, President Joe Biden has said that the ... Read the Full Story |
|
Markets | | | Kraft-Heinz (NASDAQ: KHC), Reynolds Consumer Products (NASDAQ: REYN), and Newell Brands (NASDAQ: NWL) have more in common than their status as consumer-staples companies. Not only are they deep-values relative to the broad market and their industry group they give a high yield, have safe distributions, an outlook for dividend growth, are in the midst of currently-successful growth initiatives, and the institutions are buying them. Read the Full Story |
|
|
Politics | | | The Defense Department is releasing a report that says mergers and consolidation among its contractors pose risks to the U.S. economy and national security.
Senior Biden administration officials previewed the report on the condition of anonymity ahead of its release Tuesday. The repor... Read the Full Story |
|
Politics | | | Singapore’s biennial air show opened Tuesday on a smaller scale than before the pandemic, even as the aviation sector gears up for a recovery two years after coronavirus outbreaks nearly paralyzed air travel Read the Full Story |
|
Markets | | | A spectator’s single clap echoed through the mostly empty National Aquatics Center after the British curling team knocked a Swiss stone out of position, a difficult move that usually would trigger cheers from fans.
The spectator looked around at the audience of about 200, surrounded b... Read the Full Story |
|
Markets | | | Sports entertainment and media company World Wrestling Entertainment (NYSE: WWE) stock has been on the rebound off 2022 lows driven by both top and bottom-line improvement. The popular pro wrestling brand survived through the pandemic lockdowns until the reopening and resumption of live events. The ... Read the Full Story |
|
Markets | | | Enterprise cloud workflow software solutions provider Upland Software (NASDAQ: UPLD) stock may have put in a bottom heading into its earnings. The enterprise software company already set the bar low with lowered guidance set forth in its Q3 2021 earnings release. This sent shares plunging to a recen... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | | View Today's Stock Pick |
|
